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Purpose: Initiation of hemodialysis frequently requires temporary central venous cathe- 
terization, which leads to subsequent venous stenosis in 50% of patients. These lesions 
severely limit upper extremity dialysis fistula creation. The present study was undertaken 
to determine whether early cannulation (EC) allowed omission of temporary venous 
catheterization without affecting perioperative morbidity and long-term graft patency. 
Methods: Seventy-nine prosthetic grafts for hemodialysis were placed in 76 patients over a 
40-month period. Patients who required hemodialysis between 24 and 72 hours after 
surgery were assigned to EC. The remaining rafts underwent late cannulation (LC) after 
postoperative day 14. All grafts were constructed with a 6 mm stretch-expanded polytet- 
rafluoroethylene conduit in the brachial artery-to-axillary vein position. Statistical anal- 
ysis of cumulative primary patency estimates and patient survival data were determined 
by Kaplan-Meier analysis and log-rank test, patient variables were compared using X 2 and 
Fisher's exact test, and multivariate analysis was performed using Cox's proportional 
hazard model. 
Results: Forty-eight patients underwent EC and 31 underwent LC. There were no 
significant differences regarding age (mean, 61.5 years), history of diabetes, congestive 
heart failure, hematocrit level (mean, 30%), or presence of peripheral vascular disease. 
Thrombosis occurred before cannulation in one of 48 ECs (2.0%) and one of 31 LCs 
(3.2%). There were no episodes of cannulation hemorrhage or wotmd infection in either 
group. Cumulative primary patency estimates for EC were 0.89, 0.82, and 0.70 at 3, 6, 
and 12 months, respectively. These were not significantly different from the LC estimates 
of 0.86, 0.78, and 0.74 at 3, 6, and 12 months, respectively. Overall, patients who had a 
history of peripheral vascular disease had a significantly decreased 12-month patency rate 
(60% vs 74%; p = 0.05). Central venous catheters were omitted in 47 of 48 EC patients. 
Conclusion: EC of prosthetic dialysis grafts does not increase perioperative morbidity 
rates or decrease 12-month cumulative primary patency rates. (J Vasc Surg 1997; 
25:1002-6.) 
Maintenance of access for chronic hemodialysis 
remains a formidable challenge. As the age of the 
dialysis population and the waiting period for renal 
transplantation increase, hemodialysis access must be 
available for longer periods of time. Unfortunately, 
the initiation of hemodialysis  not always a planned 
event. In the past, central venous dialysis catheters 
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have been applied liberally to this patient population. 
Unfortunately, when these catheters are placed 
through a subclavian vein insertion site, 90% of pa- 
tients have been documented to have development 
of lesions ranging from 70% stenosis to occlusion. ~ 
Moreover, these lesions may remain asymptomatic 
until the creation of a distal high-flow dialysis fistula, 
resulting in arm edema and fistula thrombosis. 2-S 
Once identified, these lesions remain problematic; 
percutaneous angioplasty alone results in a dismal 
12-month patency rate of 30%, and angioplasty with 
stent placement yields a 9-month patency rate 20% to 
47%.6 s Superior results after major venous recon- 
struction procedures have been reported. 9 These 
findings have resulted in a plea for use of  the internal 
jugular vein insertion site, which does not lead to 
subclavian vein stenosis. ~,6 However, this method of  
catheter insertion is not uniformly successful. Early 
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Table I. Characteristics of 79 brachial artery-to-axillary vein sePTFE dialysis grafts placed in 
76 patients 
Age Early Prior HCT 
Patients (mean + SD) F:M TBX distal A VF DM A VF ASA CHF EPO P VD (mean +_ SD) 
Early (n = 46) 61 + 3 24:22 2.0% 83% 61% 48 85%* 61% 90% 44% 29 + 1 
Late (n = 30) 62 + 4 0:30* 3.2% 81% 55% 31 23% 68% 96% 55% 31 -+ 0.5 
/7, Female; M, male; TBX, thrombosis; AVF, arteriovenous fistula; DM, diabetes; ASA, aspirin; CHF, congestive heart failure; EPO, 
erythropoietin; PVD, peripheral vascular disease; HCT, hematocrit. 
*p = 0.00l. 
cannulation (EC) of prosthetic dialysis grafts would 
obviate the need for central venous catheters. 
The initial experience with EC ofnonautogenous 
(bovine carotid heterograft and expanded polytetra- 
fluoroethylene [ PTFE]) dialysis fistulae was disap- 
pointing. Several reports documented tunnel hema- 
toma formation in as many as 75% of patients, which 
led to the abandonment of this practice. ~°-13 Subse- 
quently, a retrospective review of 299 nonautog- 
enous grafts that were placed within a smaller-diam- 
eter 7 mm tunnel and underwent cannulation within 
72 hours of construction was reported. This modifi- 
cation resulted in a decrease in hemorrhagic compli- 
cations to 2%. 14 Unfortunately, the impact of EC on 
long-term patency rates was not addressed. Recently, 
the results of a prospective randomized trial that 
compared ePTFE and stretch-expanded polytetra- 
fluoroethylene (sePTFE) forearm dialysis grafts can- 
nulated within 14 days of surgery has been reported. 
This small series revealed an improved patency rate 
and fewer stenoses in the sePTFE cohort, is 
The present study was undertaken to determine 
whether EC of 6 mm sePTFE brachial artery-to- 
axillary vein dialysis grafts allowed omission of tem- 
porary central venous catheterization without affect- 
ing perioperative morbidity rates and long-term 
patency rates. 
METHODS 
Patient information. From October 1992 
through February 1996, a total of 79 brachial artery- 
to-axillary vein sePTFE arteriovenous fistulae 
(AVFs) were constructed for chronic hemodlalysis 
access in 52 men and 24 women; the patients' mean 
age was 61.5 years (range, 38 to 84 years). Distal 
AVFs had previously been constructed in 62 patients 
(82%). No patient had a history of ipsilateral central 
venous catheterization, warfarin therapy, or a history 
of a previous AVF at the proposed operative location. 
EC was defined as cannulation with a 16-gauge 
needle between 24 hours and 72 hours after surgery. 
In addition, digital pressure was used to obtain can- 
nulation-site hemostasis. Late cannulation (LC) was 
defined as cannulation with a 15- or 16-gauge needle 
after the fourteenth day after surgery. Intradialytic 
heparinization and length of treatment did not differ 
between the cannulation groups. All patients who 
were assigned to EC would have required repeated 
femoral cannulation for temporary hemodialysis ac- 
cess. 
Operative technique. Fistulae were created 
with the patient under local (1% lidocaine) or general 
anesthesia. In the early period of the study, 1 gm 
intravenous vancomycin was used for perioperative 
prophylaxis. This practice was subsequently changed 
to using 1 gm cefazolin as a result of the emergence 
of vancomycin-resistant e erococci. Tunnels were 
created as a gentle curve along the lateral aspect of 
the biceps muscle using a 6 mm tunneling device 
(Impra, Inc., Flagstaff, Ariz.) through which a 6 mm 
sePTFE graft (W.L. Gore, Inc., Flagstaff, Ariz.) was 
placed. Patients received 30 U /kg  intravenous hepa- 
rin after tunnel creation. The venous anastomosis 
was constructed with continuous 6-0 polypropylene 
suture, after spatulation to 8 mm. Lastly, the arterial 
anastomosis was created without spatulation. 
Statistical analysis. Survival and cumulative pri- 
mary patency estimates were determined by Kaplan- 
Meier technique (Lifetest, SAS Institute, Inc., Cary, 
N.C.). Comparison of estimates was performed with 
log-rank test. Cox's proportional hazards model was 
used to construct univariate analysis, and X 2 and 
Fisher's exact tests were used to compare categoric 
patient variables. Data are reported as mean -+ SE. 
RESULTS 
No deaths, wound infections, or hemorrhagic 
complications occurred within 30 days of the opera- 
five procedure. The follow-up interval extended to 
40 months (mean, 22 months; median, 14 months). 
Forty-six patients underwent EC of 48 grafts, 
whereas 30 patients underwent LC of 31 grafts (Ta- 
ble I). Significant differences between groups in- 
cluded a lack of women in the LC group and greater 
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Table II. Cumulative survival and primary patency estimates 
EC (n = 48) LC (n = 31) Total (n = 79) 
No. % No. % No. % 
Survivalrate 
1 yr 20 67 
Pfimarypatencyesfimate 
3mo 42 94 
6mo 39 89 
9mo 34 82 
12 mo 29 70 
34 74 54 71 
29 97 71 95 
24 86 63 88 
18 78 52 81 
15 74 44 71" 
*p = 0.10. 
Table II I . Interval dialysis graft thrombosis 
Time 
interval 
(months) 
EC LC Total 
No (%) No (%) No (%) 
0 to 3 3/42 (7) 1/29 (3.4) 4/71 (5.6) 
3 to 6 2/39 (5) 3/24 (12.5) 5/63 (7.9) 
6 to 9 3/34 (8.8) 2/18 (11) 5/52 (9.6) 
9 to 12 3/29 (10.3) 2/15 (13.5) 5/44 (11.3) 
aspirin use in the EC group (p = 0.'001). One graft 
thrombosed before cannulation i  each group. After 
thrombectomy, a fistulogram revealed a silent sub- 
clavian stenosis in each case. These were successfully 
treated with percutaneous angioplasty and stent 
placement. 
Three additional AVFs were created in two EC 
patients and one LC patient. These followed unsuc- 
cessful thrombectomy 4, 6, and 13 months after 
initial AVF creation. Cumulative patient survival es- 
timates were not significantly different between 
groups (EC 67% vs LC 74%; p = 0.50). 
The primary patency rate for the EC group 
(mean, 12 + 1.1 months) was not significantly dif- 
ferent han that of the LC group (mean, 11.7 + 1.2 
months; p = 0.50). Primary patency estimates at 
3-month intervals were determined (Table II). There 
were no significant differences between groups at any 
interval (p = 0.10). There were no significant differ- 
ences in cumulative primary patency estimates be- 
tween patients with diabetes and patients without 
diabetes (p = 0.66; relative risk ratio, 1.137; 95% 
confidence interval, 0.637 to 2.029) regardless of 
cannulation group. However, patients who had a 
history of peripheral vascular disease had a signifi- 
cantly decreased 12-month cumulative primary pa- 
tency estimate (60% vs 74%; p = 0.05; relative risk 
ratio, 1.8; 95% confidence interval, 1.004 to 3.284) 
regardless of cannulation group. 
EC allowed for omission of central venous cathe- 
terization after 47 of 48 AVF procedures. Interval 
AVF thrombosis was compared between cannularion 
groups (Table III). Overall, thrombotic episodes in- 
creased after the 6-month interval; however, there 
were no significant differences between cannulation 
groups (p = 0.50). 
DISCUSSION 
The purpose of this study was to determine 
whether EC of sePTFE dialysis grafts would allow 
the omission of temporary venous catheterization 
without affecting perioperative morbidity rates and 
long-term patency rates. Recently, the results of a 
prospective randomized trial of 8 ePTFE and 12 
sePTFE AVFs cannulated within 14 days of creation 
were reported, ls Estimates of cumulative primary 
patency at 1 year were significantly different with 
ePTFE (29%) compared with sePTFE (59%; p < 
0.01). Our results of  70% for EC of  sePTFE AVFs 
are similar, and are in agreement with historic 
patency estimates of  ePTFE AVFs that are cannu- 
lated more than 14 days after surgery. 16J7 Esti- 
mates of AVF thrombosis risk was calculated at 
3-month intervals to determine whether EC was 
associated with more rapid thrombosis (Table III). 
However, there were no significant differences be- 
tween groups. 
Interestingly, a history of diabetes did not affect 
cumulative primary patency estimates, regardless of 
cannulation group. However, other investigators 
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have reported a decreased primary patency rate in 
this pat ient populat ion.  18 Both female gender and 
aspirin use were significantly more common in the 
EC group than in the LC group. The reasons for 
these findings remain unclear, a l though the latter did 
not  result in increased hemorrhagic omplications. 
The factors that al low for safe EC o f  the sePTFE 
grafts in the present study appear to be twofold. 
First, as described in earlier eports,  by decreasing the 
diameter o f  the subcutaneous tunnel  to closely ap- 
proximate the diameter o f  the conduit ,  the incidence 
o f  cannulat ion and tunnel  hematomas was decreased 
to 2%. 14 Second, a l though the exact compliance 
characteristics o f implanted sePTFE grafts have not  
been fully elucidated, it appears that the longitudinal  
stretch propert ies that are unique to these grafts may 
contr ibute to the improved pr imary patency rates. 16 
EC o f  sePTFE brachial artery-to-axi l lary vein 
dialysis grafts does not  appear to increase periopera- 
five morbid i ty  rates or decrease cumulative primary 
patency rates. This allows for avoidance o f  temporary 
venous catheters and the associated risk o f  central 
venous stenosis. On  the basis o f  these results, all 
patients should be considered for EC o f  dialysis 
grafts constructed as described herein. 
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DISCUSSION 
Dr. Kevin J. McBride (Boston, Mass.). My questions 
don't really regard patency data, but I found that in EC 
after a recent loop graft has been placed in the forearm that 
there is a fair amount of swelling, redness, and erythema, 
and the nurses are usually calling me because they think it is 
infected, so one question is the instance of infection or 
related cellulitis while cannulating the first couple of days. 
The second issue is one of bleeding around the graft, 
that they are not well incorporated into the subcutaneous 
tissue so that when you withdraw your needles there is a 
certain instance of subcutaneous hematoma. Did you find 
that in any significant numbers? 
Dr. Albert G. Hakaim. With regard to cannulation 
and the tunnels, these are 6 mm tunnels that are the same 
diameter as the grafts, so there isn't much of an interspace 
between the tunnel and the graft. In the earlier experience 
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with EC, they used 8 mm tunnels, and I think that's what 
caused the majority of the bleeding complications. If digi- 
tal pressure is used at the cannulation sites, which admit- 
tedly is difficult to predict in some dialysis centers, there 
isn't a problem with bleeding into the tunnel. 
Regarding your first question concerning erythema of 
forearm fistula after cannulation, these were all upper arm 
fistulae. There are patients who have some erythema long 
the tunnel, and it is difficult o tell whether it is a so-called 
tunnel reaction to the PTFE or whether it's related to an 
early infection. I think most of those are treated with 
prophylactic antibiotics. We didn't have any infections in 
this group. 
Dr. Frank B. Pomposell i  (Boston, Mass.). Your graft 
configuration is not the usual primary prosthetic graft, that 
is, it's not a loop or straight graft ending at the antecubital 
vein. Is this your preferred prosthetic graft configuration, 
and if so, why? 
Dr. Hakaim. In more than 80% of the patients in each 
group, there was a previous distal forearm graft, either a 
straight graft or a loop graft, so these were secondary 
procedures in more than 80% of the patients. We prefer to 
use autogenous graft first, or basilic vein transpositions a a 
second choice, so these patients had no antecubital venous 
capability. Therefore, upper arm fistulae were created, but 
they are not our first choice. 
